Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension

[1]  N. Greig,et al.  The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial , 2023, Brain : a journal of neurology.

[2]  A. Sinclair,et al.  The idiopathic intracranial hypertension prospective cohort study: evaluation of prognostic factors and outcomes , 2022, Journal of Neurology.

[3]  S. Helmy,et al.  Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes. , 2022, Diabetes & metabolic syndrome.

[4]  T. Wadden,et al.  Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension , 2022, Diabetes, obesity & metabolism.

[5]  H. Zeng,et al.  Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis , 2022, Endocrine.

[6]  R. Jensen,et al.  Understanding the link between obesity and headache- with focus on migraine and idiopathic intracranial hypertension , 2021, The Journal of Headache and Pain.

[7]  Linh H. Lieu,et al.  Glucagon‐like peptide‐1 (GLP‐1) signalling in the brain: From neural circuits and metabolism to therapeutics , 2021, British journal of pharmacology.

[8]  T. Wadden,et al.  Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss , 2021, Diabetes, obesity & metabolism.

[9]  U. Wüllner,et al.  The patients’ perspective on the burden of idiopathic intracranial hypertension , 2021, The Journal of Headache and Pain.

[10]  A. Sinclair,et al.  Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension , 2021, The Journal of Headache and Pain.

[11]  J. Schuman,et al.  APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies , 2021, Neurology.

[12]  S. Hickman,et al.  Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension , 2021, JAMA neurology.

[13]  K. Gokoffski,et al.  Updates on Recent Developments in Idiopathic Intracranial Hypertension , 2021, SN Comprehensive Clinical Medicine.

[14]  A. Astrup,et al.  Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data , 2021, International Journal of Obesity.

[15]  V. Bonavita,et al.  Headache in idiopathic intracranial hypertension. A CGRP-dependent head pain? , 2020, Neurological Sciences.

[16]  J. Holst.  From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy , 2019, Front. Endocrinol..

[17]  D. Friedman.  Headaches in Idiopathic Intracranial Hypertension , 2019, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[18]  E. Frew,et al.  The expanding burden of idiopathic intracranial hypertension , 2018, Eye.

[19]  K. Digre,et al.  Idiopathic intracranial hypertension: consensus guidelines on management , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[20]  D. Drucker.  Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. , 2018, Cell metabolism.

[21]  R. Jensen,et al.  A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus , 2017, Science Translational Medicine.

[22]  A. Darzi,et al.  Bariatric Surgery or Non-surgical Weight Loss for Idiopathic Intracranial Hypertension? A Systematic Review and Comparison of Meta-analyses , 2016, Obesity Surgery.

[23]  F. Barkhof,et al.  GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans , 2014, Diabetes.

[24]  John S Werner,et al.  Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part II: correlations and relationship to clinical features. , 2014, Investigative ophthalmology & visual science.

[25]  D. Drucker,et al.  Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. , 2014, The Journal of clinical investigation.

[26]  M. Marciani,et al.  Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children , 2014, Neurology.

[27]  A. Vella,et al.  Effects of GLP-1 on appetite and weight , 2014, Reviews in Endocrine and Metabolic Disorders.

[28]  U. Schmidt-Erfurth,et al.  Effectiveness of averaging strategies to reduce variance in retinal nerve fibre layer thickness measurements using spectral-domain optical coherence tomography , 2013, Graefe's Archive for Clinical and Experimental Ophthalmology.

[29]  R. Jensen,et al.  Idiopathic intracranial hypertension is not benign: a long-term outcome study , 2012, Journal of Neurology.

[30]  Axel Petzold,et al.  The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment , 2012, PloS one.

[31]  A. Kesler,et al.  OCT assessment of morphological changes of the optic nerve head and macula in idiopathic intracranial hypertension , 2011, Clinical Neurology and Neurosurgery.

[32]  A Vighetto,et al.  Detection of mild papilloedema using spectral domain optical coherence tomography , 2011, British Journal of Ophthalmology.

[33]  D. Yabe,et al.  Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference , 2011, Clinical medicine insights. Endocrinology and diabetes.

[34]  C. Clarke,et al.  Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study , 2010, BMJ : British Medical Journal.

[35]  K. Parhofer.  [Glucagon-like peptide 1 (GLP-1)]. , 2007, MMW Fortschritte der Medizin.

[36]  N. Newman,et al.  Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). , 2007, American journal of ophthalmology.

[37]  Fred W Fitzke,et al.  How sensitive to clinical change are ETDRS logMAR visual acuity measurements? , 2003, Investigative ophthalmology & visual science.

[38]  H. Koppeschaar,et al.  Calcitonin gene-related peptide in human obesity , 1991, Peptides.

[39]  H. S. Thompson,et al.  Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. , 1982, Archives of neurology.

[40]  L Frisén,et al.  Swelling of the optic nerve head: a staging scheme , 1982, Journal of neurology, neurosurgery, and psychiatry.

[41]  Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. , 1991, Ophthalmology.

[42]  H R Atta,et al.  Imaging of the optic nerve with standardised echography , 1988, Eye.

[43]  K. Ossoinig.  A-scan echography and orbital disease. , 1975, Modern problems in ophthalmology.